My daughter’s annual pharmacy bill is routinely a multiple of my salary as a state employee whose family relies on the health benefits that come with my job. That grim ...

Wolfe Research initiated coverage of Bristol Myers (BMY) with a Peer Perform rating. The firm said there maybe a comeback story with Bristol, ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

The biopharma industry is on an upward trajectory, driven by groundbreaking advances in treatment options and a rising demand ...

BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

Bristol Myers Squibb’s robust cardiovascular portfolio and significant upcoming data presentations at the AHA meeting are positioning the company as a key player in the fight against cardiovascular ...